Cepharanthine Reverses Gefitinib Resistance in NSCLC by Concurrently Inhibiting AKT / P70S6K Survival Signaling and Activating STING ‐Mediated Immune Response
Chemical Biology & Drug Design · 2026
DOI: 10.1111/cbdd.70298 ↗At a glance
Journal article in Chemical Biology & Drug Design, 2026. Written by Li-Ping Kang and 6 co-authors. Institution: Zhuhai Hospital of Integrated Traditional Chinese and Western Medicine, Zhuhai, Guangdong, China. Major MEDLINE topics: Benzylisoquinolines, Gefitinib, Proto-Oncogene Proteins c-akt, Carcinoma, Non-Small-Cell Lung. Cited 1 times so far (Crossref); 37 references. Funded by: Guangdong Basic and Applied Basic Research Foundation, China Postdoctoral Science Foundation, Guangdong Provincial Bureau of Traditional Chinese Medicine.
Abstract (original language)
Acquired resistance to Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitors (TKIs), such as gefitinib, remains a major therapeutic challenge in EGFR‐mutant non‐small cell lung cancer (NSCLC). Here, we report that cepharanthine (CEP), a natural bisbenzylisoquinoline alkaloid, effectively reverses gefitinib resistance through concurrent suppression of the AKT/P70S6K survival axis and activation of the Stimulator of Interferon Genes (STING)‐mediated innate immune pathway. In gefitinib‐resistant H1975 cells (EGFR L858R/T790M), CEP monotherapy significantly inhibited proliferation and induced mitochondrial apoptosis. Notably, CEP synergized with gefitinib to enhance therapeutic efficacy. RNA sequencing and functional validation revealed that CEP activates the STING/TANK‐Binding Kinase 1 (TBK1)/Interferon Regulatory Factor 3 (IRF3) signaling cascade, resulting in robust production of T‐cell chemoattractants C‐X‐C Motif Chemokine Ligand 9 (CXCL9), C‐X‐C Motif Chemokine Ligand 10 (CXCL10), and C‐C Motif Chemokine Ligand 5 (CCL5). Critically, the STING inhibitor H‐151 abolished CEP's antitumor effects in vitro. Our findings reveal a novel dual mechanism action of CEP and nominate it as a potential candidate for overcoming TKI resistance in NSCLC.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Zhuhai Hospital of Integrated Traditional Chinese and Western Medicine, Zhuhai, Guangdong, China.
- Northeastern University, Boston, Massachusetts, USA.
- Translational Medicine Research Center, Medical College, Dalian University, Dalian, Liaoning, China.
Funding
- Guangdong Basic and Applied Basic Research Foundation
- China Postdoctoral Science Foundation
- Guangdong Provincial Bureau of Traditional Chinese Medicine
- Zhuhai Science and Technology Innovation Bureau
- Zhuhai Hospital of Integrated Traditional Chinese & Western Medicine
- Guangdong Province-Provincial Chinese Medicine construction special fund named Traditional Chinese Medicine Inheritance Studio construction project Guangdong C…
- Medical Science and Technology Research Fund of Guangdong Province
- Beijing Chao Enxiang Traditional Chinese Medicine Heritage and Development Foundation
Cite
APA
Kang, L. P., Chen, H. H., Lv, T. T., Huang, H. J., Huang, D. H., Chen, Y. Q., & Jiang, Z. B. (2026). Cepharanthine Reverses Gefitinib Resistance in NSCLC by Concurrently Inhibiting AKT / P70S6K Survival Signaling and Activating STING ‐Mediated Immune Response. Chemical Biology & Drug Design. https://doi.org/10.1111/cbdd.70298
Vancouver
Kang LP, Chen HH, Lv TT, Huang HJ, Huang DH, Chen YQ, et al. Cepharanthine Reverses Gefitinib Resistance in NSCLC by Concurrently Inhibiting AKT / P70S6K Survival Signaling and Activating STING ‐Mediated Immune Response. Chemical Biology & Drug Design. 2026. doi:10.1111/cbdd.70298
BibTeX
@article{Kang2026,
author = {Kang, Li-Ping and Chen, Hui-Hui and Lv, Tong-Tong and Huang, Hua-Jing and Huang, Dong-Hui and Chen, Ying-Qing and Jiang, Ze-Bo},
title = {Cepharanthine Reverses Gefitinib Resistance in NSCLC by Concurrently Inhibiting AKT / P70S6K Survival Signaling and Activating STING ‐Mediated Immune Response},
journal = {Chemical Biology & Drug Design},
year = {2026},
doi = {10.1111/cbdd.70298}
}
EUVIMED